Allarity Therapeutics, Inc. financial data

Symbol
ALLR on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 234% % 156%
Debt-to-equity 73% % -67%
Return On Equity -112% % 65%
Return On Assets -65% % 35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,811,886 shares 257%
Common Stock, Shares, Outstanding 16,111,461 shares 484%
Entity Public Float $7,460,532 USD 124%
Common Stock, Value, Issued $3,000 USD
Weighted Average Number of Shares Outstanding, Basic 14,739,800 shares 835%
Weighted Average Number of Shares Outstanding, Diluted 14,979,095 shares 80342%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $6,774,000 USD -1.4%
General and Administrative Expense $10,230,000 USD 24%
Operating Income (Loss) $17,004,000 USD 31%
Nonoperating Income (Expense) $1,693,000 USD -70%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $15,311,000 USD 20%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $15,311,000 USD 18%
Earnings Per Share, Basic 658 USD/shares 98%
Earnings Per Share, Diluted 6,849 USD/shares 100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $16,895,000 USD
Other Assets, Current $113,000 USD 13%
Assets, Current $20,466,000 USD 0.49%
Property, Plant and Equipment, Net $330,000 USD 2650%
Intangible Assets, Net (Excluding Goodwill) $0 USD -100%
Assets $20,796,000 USD 2.1%
Accounts Payable, Current $4,602,000 USD -1.9%
Accrued Liabilities, Current $2,712,000 USD 105%
Liabilities, Current $8,785,000 USD 18%
Deferred Income Tax Liabilities, Net $0 USD -100%
Liabilities $8,785,000 USD 18%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,303,000 USD -232%
Retained Earnings (Accumulated Deficit) $126,824,000 USD -14%
Stockholders' Equity Attributable to Parent $12,011,000 USD -7.4%
Liabilities and Equity $20,796,000 USD 2.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,686,000 USD -92%
Net Cash Provided by (Used in) Financing Activities $11,143,000 USD 707%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 18,712,224 shares 578%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16,900,000 USD -8.6%
Deferred Tax Assets, Valuation Allowance $21,078,000 USD 26%
Deferred Tax Assets, Gross $21,078,000 USD 29%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $16,920,000 USD 9.6%
Deferred Income Tax Expense (Benefit) $14,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $19,325,000 USD 14%
Preferred Stock, Shares Issued 0 shares -100%
Additional Paid in Capital $143,841,000 USD 15%
Preferred Stock, Shares Outstanding 0 shares -100%
Depreciation, Depletion and Amortization $11,000 USD 450%
Share-based Payment Arrangement, Expense $132,000 USD 676%
Interest Expense $508,000 USD 84%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%